Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature

Table 2

Phase III trials of somatostatin analogs and molecular targeting therapy in advanced NETs.

Tumor type and treatment regimen	Patients (number)	ORR (%)	Median PFS (months)	Median TTP (months)	Criteria
Pancreatic NETs
Raymond et al. [71]					RECIST
Sunitinib	86	9		11.4
Placebo	8	0		5.5
Yao et al. [72] (RADIANT-3 study)					RECIST
Everolimus	207		11.0
Placebo	203		4.6
Small bowel NETs
Rinke et al. [65] (PROMID study)					WHO
Octreotide LAR	42	2		14.3
Placebo	43	2		6.0
Pavel et al. [73] (RADIANT-2 study)					RECIST
Everolimus + octreotide LAR	211		16.4
Placebo + octreotide LAR	204		11.3
Small bowel and pancreatic NETs
Caplin et al. [62] (CLARINET study)					RECIST
Lanreotide autogel	101		Not achieved
Placebo	103		18.0
Small bowel and lung NETs
Yao et al. [74] (RADIANT-4 study)					RECIST
Everolimus	205		11.0
Placebo	97		3.9

ORR, overall response rate; PFS, progression-free survival; TTP, time to progression; RECIST, Response Evaluation Criteria in Solid Tumors; LAR, long-acting release; WHO, World Health Organization tumor response criteria.